Dose modification of alemtuzumab in combination with dexamethasone, cytarabine, and cisplatin in patients with relapsed or refractory peripheral T-cell lymphoma: analysis of efficacy and toxicity
- 24 August 2010
- journal article
- research article
- Published by Springer Nature in Investigational New Drugs
- Vol. 30 (1) , 368-375
Abstract
Background There is still no consensus on the role of alemtuzumab as a salvage therapy for relapsed or refractory peripheral T-cell lymphoma (PTCL). We studied the efficacy and toxicity of combination treatment of alemtuzumab, dexamethasone, cytarabine, and cisplatin (A-DHAP) for treating PTCL. Methods We enrolled 24 patients with relapsed or refractory PTCL. Each patient received DHAP plus alemtuzumab every 3 weeks for up to three cycles. Two alemtuzumab dosages of 70 mg or 40 mg were used per cycle. After A-DHAP treatment, the responders underwent autologous stem cell transplantation. Results The overall response rate was 50.0% (12 of 24 patients), including five complete responders and seven partial responders. Analysis of the responses according to histological type showed a higher objective response rate for PTCL-unspecified (69.2%: four complete responders, five partial responders) than for extranodal NK/T cell lymphoma (12.5%, one partial responder). The median overall survival (OS) after enrollment was 6.0 months (95% confidence interval: 4.20–7.80 months), and the median response duration of responders was 2.93 months (95% confidence interval: 0.93–4.93 months). The overall response rate and OS did not differ significantly according to the dosage of alemtuzumab (70 mg vs. 40 mg, P > 0.05). The most frequent side effect was grade 3/4 leukopenia. Non-disease-related death occurred more frequently in patients who received 70 mg of alemtuzumab. Conclusions The combination of alemtuzumab plus DHAP might be effective salvage chemotherapy for PTCL, and 40 mg of alemtuzumab appears to be a more tolerable dosage when used in combination with DHAP.Keywords
This publication has 25 references indexed in Scilit:
- Characteristics and stage of the underlying diseases could determine the risk of opportunistic infections in patients receiving alemtuzumabHaematologica, 2008
- Alemtuzumab in clinical practice: A British Columbia experienceLeukemia & Lymphoma, 2008
- IMVP-16/Pd followed by high-dose chemotherapy and autologous stem cell transplantation as a salvage therapy for refractory or relapsed peripheral T-cell lymphomasLeukemia & Lymphoma, 2005
- A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomasBlood, 2004
- Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical studyBlood, 2004
- Cellular immune reconstitution after subcutaneous alemtuzumab (anti-CD52 monoclonal antibody, CAMPATH-1H) treatment as first-line therapy for B-cell chronic lymphocytic leukaemiaLeukemia, 2004
- Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international studyBlood, 2002
- Combination of 13-cis Retinoic Acid and Interferon-α in the Treatment of Recurrent or Refractory Peripheral T-cell LymphomaLeukemia & Lymphoma, 2002
- Immunohistochemical analysis of CDw52 antigen expression in non-Hodgkin's lymphomas.Journal of Clinical Pathology, 1994
- Optimal two-stage designs for phase II clinical trialsControlled Clinical Trials, 1989